Top Markets
#1 Prom Prom +36.71%
#2 QuantixAI QuantixAI +31.15%
#3 MowCat MowCat +29.37%
#4 UnifAI Network UnifAI Network +29.28%
#5 GEKKO GEKKO +23.69%
#6 MarsCoin MarsCoin +22.62%
#7 DOG•GO•TO•THE•MOON (Runes) DOG•GO•TO•THE•MOON (Runes) +20.59%
#8 Kinesis Silver Kinesis Silver +19.20%
#9 Versatize Coin Versatize Coin +16.67%
#10 Derive Derive +14.36%
Coin of the day
Prom Prom
Settings
Language
ENGLISH
Currency
USD
Theme
Captor Therapeutics Spolka Akcyjna Captor Therapeutics Spolka Akcyjna

Captor Therapeutics Spolka Akcyjna

CTX
Rank in Stocks #20489
Captor Therapeutics Spolka Akcyjna, a biopharmaceutical company, focuses on the... Captor Therapeutics Spolka Akcyjna, a biopharmaceutical company, focuses on the discovery and development of protein degradation drugs for cancer and autoimmune diseases. The company provides Targeted Protein Degradation technology that overcomes many existing drug limitations by removing proteins resistant to available therapeutics. Its products in various stages of development include CT-03, which has completed the Phase 1 clinical trials for the treatment of non-small cell lung cancer, triple-negative breast cancer, as well as cancers of the blood, lymphatic system, and bone marrow; and CT-01, which also completed the Phase 1 clinical trials for the treatment of hepatocellular carcinoma, through degradation of oncofetal transcription factor. The company was incorporated in 2015 and is headquartered in Wroclaw, Poland.
Share Price
$20.33
Market Cap
$128.73M
Change (1 day)
-1.10%
Change (1 year)
80.41%
Country
PL
Trade Captor Therapeutics Spolka Akcyjna (CTX)

Category

Healthcare
P/E ratio for Captor Therapeutics Spolka Akcyjna (CTX)
P/E ratio as of 2026 TTM: 0
According to Captor Therapeutics Spolka Akcyjna latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Captor Therapeutics Spolka Akcyjna from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.